Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...

Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be aware of the most powerful shareholder groups. With 78% stake, institutions possess the maximum shares in the company.

Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenefy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...